Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area-Reference-Cited by-同舟云学术

Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area

Published:2018 Issue:1 Volume:61 Page:058-065
ISSN:1346-8049
Container-title:Yonago Acta Medica
language:en
Short-container-title:Yonago Acta Med.

Author:

Hosoda Yuzuru¹²,Hino Norihiko²,Motokura Toru¹

Affiliation:

1. *Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan

2. †Department of Hematology, Tottori University Hospital, Yonago 683-8504, Japan

Publisher

Tottori University Faculty of Medicine

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/yam/61/1/61_2018.03.008/_pdf

Reference18 articles.

1. 1 The International Non-Hodgkin’s Lymphoma Prognostic Factors Project.A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987-94. doi: 10.1056/NEJM199309303291402 PMID: 8141877

2. 2 Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al.The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-61. doi: 10.1182/blood-2006-08-038257 PMID: 17105812

3. 3 Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, et al.Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010;151:143-51. doi: 10.1111/j.1365-2141.2010.08331.x PMID: 20735398 PMCID: PMC3615251

4. 4 Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al.An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837-42. doi: 10.1182/blood-2013-09-524108 PMID: 24264230

5. 5 Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al.Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31:3971-9. doi: 10.1200/JCO.2013.50.4910 PMID: 24101038 PMCID: PMC5569679

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review;Leukemia;2020-07-10

2. Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review;Critical Reviews in Oncology/Hematology;2019-01